D4S0 logo

Daiichi Sankyo Company DB:D4S0 Stock Report

Last Price

€20.40

Market Cap

€40.7b

7D

-1.9%

1Y

n/a

Updated

17 Mar, 2025

Data

Company Financials +

Daiichi Sankyo Company, Limited

DB:D4S0 Stock Report

Market Cap: €40.7b

D4S0 Stock Overview

Manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. More details

D4S0 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance4/6
Financial Health5/6
Dividends3/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Daiichi Sankyo Company, Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Daiichi Sankyo Company
Historical stock prices
Current Share PriceJP¥20.40
52 Week HighJP¥29.80
52 Week LowJP¥20.40
Beta0.18
1 Month Change-8.93%
3 Month Change-18.40%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-22.73%

Recent News & Updates

Recent updates

Shareholder Returns

D4S0DE PharmaceuticalsDE Market
7D-1.9%1.2%1.6%
1Yn/a-11.2%16.4%

Return vs Industry: Insufficient data to determine how D4S0 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how D4S0 performed against the German Market.

Price Volatility

Is D4S0's price volatile compared to industry and market?
D4S0 volatility
D4S0 Average Weekly Movement4.7%
Pharmaceuticals Industry Average Movement4.2%
Market Average Movement5.4%
10% most volatile stocks in DE Market12.0%
10% least volatile stocks in DE Market2.8%

Stable Share Price: D4S0 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine D4S0's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
189918,726Sunao Manabewww.daiichisankyo.com

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent.

Daiichi Sankyo Company, Limited Fundamentals Summary

How do Daiichi Sankyo Company's earnings and revenue compare to its market cap?
D4S0 fundamental statistics
Market cap€40.66b
Earnings (TTM)€1.51b
Revenue (TTM)€11.03b

26.9x

P/E Ratio

3.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
D4S0 income statement (TTM)
RevenueJP¥1.80t
Cost of RevenueJP¥426.02b
Gross ProfitJP¥1.37t
Other ExpensesJP¥1.12t
EarningsJP¥245.77b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 25, 2025

Earnings per share (EPS)130.92
Gross Margin76.28%
Net Profit Margin13.68%
Debt/Equity Ratio6.2%

How did D4S0 perform over the long term?

See historical performance and comparison

Dividends

1.7%

Current Dividend Yield

47%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/17 15:46
End of Day Share Price 2025/03/17 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Daiichi Sankyo Company, Limited is covered by 32 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
null nullBNP Paribas Securities (Asia)
Koichi MameganoBofA Global Research